# A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

> **NCT00729872** · PHASE1,PHASE2 · COMPLETED · sponsor: **ActoGeniX N.V.** · enrollment: 60 (estimated)

## Conditions studied

- Moderately Active Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** AG011
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00729872
- **Lead sponsor:** ActoGeniX N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2009-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729872, "A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00729872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*